The similar cytotoxicity of CD56dimNKG2A−KIR+ NK cells from IM and PTLD patients argues against different KIR mediated licensing due to different HLA class I distribution in the two patient cohorts (29). The gene discussed is KIR3DL1; the disease is post-transplant lymphoproliferative disease.